1. Andersson, B. S., Collins, V., Kurzrock, R., Larkin, D., Childs, C., Ost, A., Cork, A., Trujillo, J., Freireich, E., & Siciliano, M. (1995). Kbm-7, a human myeloid leukemia cell line with double philadelphia chromosomes lacking normal C-Abl and Bcr transcripts. Leukemia, 9, 2100–2108.
2. Barnes, P. J. (2013). Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 131, 636–645.
3. Buch, M. H., Conaghan, P. G., Quinn, M. A., Bingham, S. J., Veale, D., & Emery, P. (2004). True infliximab resistance in rheumatoid arthritis: A role for lymphotoxin α? Annals of the Rheumatic Diseases, 63, 1344–1346.
4. Diaz-Borjon, A., Richaud-Patin, Y., Jakez-Ocampo, J., Ruiz-Argüelles, A., & Llorente, L. (2000). Multidrug resistance-1 (Mdr-1) in rheumatic autoimmune disorders. Part II: Increased p-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint, Bone, Spine, 67, 40–48.
5. Finckh, A., Dudler, J., Wermelinger, F., Ciurea, A., Kyburz, D., Gabay, C., & Bas, S. (2010). Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint, Bone, Spine, 77, 313–318.